In vitro antileishmanial activity of resveratrol and its hydroxylated analogues against Leishmania major promastigotes and amastigotes

Parasitology Research

Volumn 102, Issue 1, 2007, Pages 91-97

  Kedzierski, Lukasz ^a,c   Curtis, Joan M ^a   Kaminska, Milena ^b   Jodynis Liebert, Jadwiga ^b   Murias, Marek ^b,c  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c NONE   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

3,4,4',5' TETRAHYDROXY STILBENE; ANTILEISHMANIAL AGENT; RESVERATROL; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

AMASTIGOTE; ARTICLE; CELL ASSAY; CONCENTRATION (PARAMETERS); CYTOTOXICITY TEST; DOSE RESPONSE; DRUG POTENCY; IC 50; IN VITRO STUDY; INTRACELLULAR MEMBRANE; LEISHMANIA MAJOR; LIFE CYCLE; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LEISHMANIA MAJOR; MACROPHAGES; MICE; STILBENES;

ANIMALIA; KINETOPLASTIDA; LEISHMANIA MAJOR; VITACEAE;

EID: 35448952986     PISSN: 09320113     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00436-007-0729-y     Document Type: Article

References (35)

1. Babich H, Reisbaum AG, Zuckerbraun HL (2000) In vitro response of human gingival epithelial S-G cells to resveratrol. Toxicol Lett 114:143-153
2. Baur JA, Sinclair DA (2006) Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5:493-506
3. Chan MM (2002) Antimicrobial effect of resveratrol on dermatophytes and bacterial pathogens of the skin. Biochem Pharmacol 63:99-104
4. Croft SL, Engel J (2006) Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans R Soc Trop Med Hyg
5. Crowell JA, Korytko PJ, Morrissey RL, Booth TD, Levine BS (2004) Resveratrol-associated renal toxicity. Toxicol Sci 82:614-619
6. Davis AJ, Kedzierski L (2005) Recent advances in antileishmanial drug development. Curr Opin Investig Drugs 6:163-169
7. del Olmo E, Armas MG, Lopez-Perez JL, Munoz V, Deharo E, San Feliciano A (2001) Leishmanicidal activity of some stilbenoids and related heterocyclic compounds. Bioorg Med Chem Lett 11:2123-2126
8. Desjeux P (2004) Leishmaniasis: current situation and new perspectives. Comp Immunol Microbiol Infect Dis 27:305-318
9. Dobrydneva Y, Williams RL, Blackmore PF (1999) trans-Resveratrol inhibits calcium influx in thrombin-stimulated human platelets. Br J Pharmacol 128:149-157
10. Docherty JJ, Fu MM, Stiffler BS, Limperos RJ, Pokabla CM, DeLucia AL (1999) Resveratrol inhibition of herpes simplex virus replication. Antivir Res 43:145-155
11. Eibl H, Unger C (1990) Hexadecylphosphocholine: a new and selective antitumor drug. Cancer Treat Rev 17:233-242
12. Falchetti R, Fuggetta MP, Lanzilli G, Tricarico M, Ravagnan G (2001) Effects of resveratrol on human immune cell function. Life Sci 70:81-96
13. Feng YH, Zhou WL, Wu QL, Li XY, Zhao WM, Zou JP (2002) Low dose of resveratrol enhanced immune response of mice. Acta Pharmacol Sin 23:893-897
14. Gao X, Xu YX, Janakiraman N, Chapman RA, Gautam SC (2001) Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol 62:1299-1308
15. Gao X, Deeb D, Media J, Divine G, Jiang H, Chapman RA, Gautam SC (2003) Immunomodulatory activity of resveratrol: discrepant in vitro and in vivo immunological effects. Biochem Pharmacol 66:2427-2435
16. Handman E (1999) Cell biology of Leishmania. Adv Parasitol 44:1-39
17. Jha TK, Sundar S, Thakur CP, Bachmann P, Karbwang J, Fischer C, Voss A, Berman J (1999) Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med 341:1795-1800
18. Juan ME, Vinardell MP, Planas JM (2002) The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 132:257-260
19. Jung HJ, Hwang IA, Sung WS, Kang H, Kang BS, Seu YB, Lee DG (2005) Fungicidal effect of resveratrol on human infectious fungi. Arch Pharm Res 28:557-560
20. Kedzierski L, Montgomery J, Bullen D, Curtis J, Gardiner E, Jimenez-Ruiz A, Handman E (2004) A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. J Immunol 172:4902-4906
21. Kelleher M, Moody SF, Mirabile P, Osborn AH, Bacic A, Handman E (1995) Lipophosphoglycan blocks attachment of Leishmania major amastigotes to macrophages. Infect Immun 63:43-50
22. Kiderlen AF, Kayser O, Ferreira D, Kolodziej H (2001) Tannins and related compounds: killing of amastigotes of Leishmania donovani and release of nitric oxide and tumour necrosis factor alpha in macrophages in vitro. Z Naturforsch [C] 56:444-454
23. Kolodziej H, Kiderlen AF (2005) Antileishmanial activity and immune modulatory effects of tannins and related compounds on Leishmania parasitised RAW 264.7 cells. Phytochemistry 66:2056-2071
24. Leiro J, Arranz JA, Parama A, Alvarez MF, Sanmartin ML (2004a) In vitro effects of the polyphenols resveratrol, mangiferin and (-)-epigallocatechin-3- gallate on the scuticociliate fish pathogen Philasterides dicentrarchi. Dis Aquat Org 59:171-174
25. Leiro J, Cano E, Ubeira FM, Orallo F, Sanmartin ML (2004b) In vitro effects of resveratrol on the viability and infectivity of the microsporidian Encephalitozoon cuniculi. Antimicrob Agents Chemother 48:2497-2501
26. Mickuviene I, Kirveliene V, Juodka B (2004) Experimental survey of non-clonogenic viability assays for adherent cells in vitro. Toxicol In Vitro 18:639-648
27. Mikus J, Steverding D (2000) A simple colorimetric method to screen drug cytotoxicity against Leishmania using the dye Alamar Blue. Parasitol Int 48:265-269
28. Murias M, Handler N, Erker T, Pleban K, Ecker G, Saiko P, Szekeres T, Jager W (2004) Resveratrol analogues as selective cyclooxygenase-2 inhibitors: synthesis and structure-activity relationship. Bioorg Med Chem 12:5571-5578
29. Murias M, Jager W, Handler N, Erker T, Horvath Z, Szekeres T, Nohl H, Gille L (2005) Antioxidant, prooxidant and cytotoxic activity of hydroxylated resveratrol analogues: structure-activity relationship. Biochem Pharmacol 69:903-912
30. Murray HW, Berman JD, Davies CR, Saravia NG (2005) Advances in leishmaniasis. Lancet 366:1561-1577
31. Redondo P, Jimenez E, Perez A, Garcia-Foncillas J (2000) N-acetylcysteine downregulates vascular endothelial growth factor production by human keratinocytes in vitro. Arch Dermatol Res 292:621-628
32. Sacks D, Noben-Trauth N (2002) The immunology of susceptibility and resistance to Leishmania major in mice. Nat Rev Immunol 2:845-858
33. Siemann EH, Creasy LL (1992) Concentration of the phytoalexin resveratrol in wine. Am J Enol Vitic 43:49-52
34. Son IH, Chung IM, Lee SJ, Moon HI (2007) Antiplasmodial activity of novel stilbene derivatives isolated from Parthenocissus tricuspidata from South Korea. Parasitol Res 101:237-241
35. Tapiero H, Tew KD, Ba GN, Mathe G (2002) Polyphenols: do they play a role in the prevention of human pathologies? Biomed Pharmacother 56:200-207